MIRM
insider transactionsMirum Pharmaceuticals, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 90d
-40.6K
0 buy · 40.6K sell
Net value · 90d
-$4.0M
$0 in · $4.0M out
Sentiment · 90d
Net selling
0% buying · 100% selling
Open-market trades · 90d
10
0 buy · 40.6K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Sell·S
SVP, GLOBAL CONTROLLER · 10b5-1
$264.5K
2.6K sh · $101.95
Own -31%
-
Grant·A
Director
$0
2.0K sh
Own New
-
Grant·A
Director
$0
3.8K sh
Own New
-
Grant·A
Director
$0
2.0K sh
Own New
-
Grant·A
Director
$0
3.8K sh
Own New
-
Grant·A
Director
$0
2.0K sh
Own New
-
Grant·A
Director
$0
3.8K sh
Own New
-
Grant·A
Director
$0
2.0K sh
Own New
-
Grant·A
Director
$0
3.8K sh
Own New
-
Exercise·M
Peter Radovich KEY
PRESIDENT AND COO
$0
17.0K sh
Own +55%
-
Exercise·M
Peter Radovich KEY
PRESIDENT AND COO
$326.0K
17.0K sh · $19.19
Own +42%
-
Exercise·M
CHIEF EXECUTIVE OFFICER · 10b5-1
$0
30.0K sh
Own +30%
-
Sell·S
CHIEF EXECUTIVE OFFICER · 10b5-1
$88.0K
883 sh · $99.66
Own -0%
-
Sell·S
CHIEF EXECUTIVE OFFICER · 10b5-1
$100.3K
1.0K sh · $98.20
Own -1%
-
Sell·S
CHIEF EXECUTIVE OFFICER · 10b5-1
$192.5K
2.0K sh · $97.56
Own -1%
-
Sell·S
CHIEF EXECUTIVE OFFICER · 10b5-1
$665.9K
6.9K sh · $96.15
Own -3%
-
Sell·S
CHIEF EXECUTIVE OFFICER · 10b5-1
$1.6M
16.6K sh · $95.34
Own -7%
-
Sell·S
CHIEF EXECUTIVE OFFICER · 10b5-1
$246.3K
2.6K sh · $94.64
Own -1%
-
Exercise·M
CHIEF EXECUTIVE OFFICER · 10b5-1
$88.1K
30.0K sh · $2.94
Own +15%
-
Sell·S
Director
$397.7K
4.0K sh · $100.00
Own -100%
-
Exercise·M
Director
$0
4.0K sh
Own New
-
Exercise·M
Director
—
4.0K sh
Own New
-
Exercise·M
Director
$0
4.0K sh
Own New
-
Exercise·M
Director
—
4.0K sh
Own +70%
-
Exercise·M
Director
$0
4.0K sh
Own New
-
Exercise·M
Director
—
4.0K sh
Own +59%
-
Exercise·M
Director
$0
4.0K sh
Own New
-
Exercise·M
Director
—
4.0K sh
Own +70%
-
Exercise·M
Director · 10b5-1
$0
2.0K sh
Own New
-
Sell·S
Director · 10b5-1
$218.9K
2.0K sh · $109.47
Own -100%
-
Exercise·M
Director · 10b5-1
$47.0K
2.0K sh · $23.51
Own New
-
Exercise·M
Director · 10b5-1
$0
2.0K sh
Own New
-
Sell·S
Director · 10b5-1
$193.8K
2.0K sh · $96.90
Own -100%
-
Exercise·M
Director · 10b5-1
$47.0K
2.0K sh · $23.51
Own New
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 17, 2026 | Jolanda Howe 10b5-1 | Sell S | 2.6K | $264.5K |
| Jun 15, 2026 | Saira Ramasastry | Grant A | 2.0K | $0 |
| Jun 15, 2026 | Saira Ramasastry | Grant A | 3.8K | $0 |
| Jun 15, 2026 | Timothy P Walbert | Grant A | 2.0K | $0 |
| Jun 15, 2026 | Timothy P Walbert | Grant A | 3.8K | $0 |
| Jun 15, 2026 | Laurent Fischer | Grant A | 2.0K | $0 |
| Jun 15, 2026 | Laurent Fischer | Grant A | 3.8K | $0 |
| Jun 15, 2026 | Lon Cardon | Grant A | 2.0K | $0 |
| Jun 15, 2026 | Lon Cardon | Grant A | 3.8K | $0 |
| Jun 5, 2026 | Peter Radovich KEY | Exercise M | 17.0K | $0 |
| Jun 5, 2026 | Peter Radovich KEY | Exercise M | 17.0K | $326.0K |
| Jun 1, 2026 | Christopher Peetz KEY 10b5-1 | Exercise M | 30.0K | $0 |
| Jun 1, 2026 | Christopher Peetz KEY 10b5-1 | Sell S | 883 | $88.0K |
| Jun 1, 2026 | Christopher Peetz KEY 10b5-1 | Sell S | 1.0K | $100.3K |
| Jun 1, 2026 | Christopher Peetz KEY 10b5-1 | Sell S | 2.0K | $192.5K |
| Jun 1, 2026 | Christopher Peetz KEY 10b5-1 | Sell S | 6.9K | $665.9K |
| Jun 1, 2026 | Christopher Peetz KEY 10b5-1 | Sell S | 16.6K | $1.6M |
| Jun 1, 2026 | Christopher Peetz KEY 10b5-1 | Sell S | 2.6K | $246.3K |
| Jun 1, 2026 | Christopher Peetz KEY 10b5-1 | Exercise M | 30.0K | $88.1K |
| Jun 1, 2026 | Saira Ramasastry | Sell S | 4.0K | $397.7K |
| May 29, 2026 | Saira Ramasastry | Exercise M | 4.0K | $0 |
| May 29, 2026 | Saira Ramasastry | Exercise M | 4.0K | — |
| May 29, 2026 | Timothy P Walbert | Exercise M | 4.0K | $0 |
| May 29, 2026 | Timothy P Walbert | Exercise M | 4.0K | — |
| May 29, 2026 | Laurent Fischer | Exercise M | 4.0K | $0 |
| May 29, 2026 | Laurent Fischer | Exercise M | 4.0K | — |
| May 29, 2026 | Lon Cardon | Exercise M | 4.0K | $0 |
| May 29, 2026 | Lon Cardon | Exercise M | 4.0K | — |
| May 15, 2026 | Saira Ramasastry 10b5-1 | Exercise M | 2.0K | $0 |
| May 15, 2026 | Saira Ramasastry 10b5-1 | Sell S | 2.0K | $218.9K |
| May 15, 2026 | Saira Ramasastry 10b5-1 | Exercise M | 2.0K | $47.0K |
| Apr 15, 2026 | Saira Ramasastry 10b5-1 | Exercise M | 2.0K | $0 |
| Apr 15, 2026 | Saira Ramasastry 10b5-1 | Sell S | 2.0K | $193.8K |
| Apr 15, 2026 | Saira Ramasastry 10b5-1 | Exercise M | 2.0K | $47.0K |
About MIRM insider trading
This page tracks insider transactions for Mirum Pharmaceuticals, Inc. (MIRM) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.